具有pH响应性载硼替佐米纳米粒靶向治疗多发性骨髓瘤OA

Objective The BTZ@PLGA-RGD nanoparticles that target integrin αvβ3 and are loaded with bortezomib(BTZ)were prepared to achieve targeted therapy for multiple myeloma(MM).Methods The emul-sion solvent evaporation method and carbodiimide chemistry method were used to form BTZ@PLGA-RGD nanopar-ticles.The characterization of BTZ@PLGA-RGD nanoparticles was confirmed with scanning electron microscopy(SEM),dynamic light scattering(DLS),and fourier-transform infrared(FTIR).BTZ@PLGA-RGD nanoparticles were evaluated in terms of stability,encapsulation efficiency,release profile,and blood compatibility.The local-ization and cytotoxicity of BTZ@PLGA-RGD were determined using confocal laser scanning microscopy(CLSM)and the CCK-8 experiment.Results BTZ@PLGA-RGD nanoparticles were in a spherical shape with a uniform size distribution.The mean particle size of BTZ@PLGA-RGD nanoparticles was(113.7±3.1)nm,accompanied by a positive surface charge of(+6.4±1.3)mV.The entrapment efficiency of the BTZ@PLGA-RGD nanoparticles was 73.32％.These nanoparticles exhibited good long-term stability and blood compatibility.BTZ@PLGA-RGD nanoparticles had pH-responsive drug release properties,and the cumulative drug release(％)over 48 h was(82.34±0.12)％.FTIR analysis indicated that BTZ was successfully loaded into the BTZ@PLGA-RGD nanopar-ticles,and RGD was successfully immobilized on the surface of the nanoparticles.The localization analysis showed that the active targeting effect mediated by the RGD peptide enabled the BTZ@PLGA-RGD nanoparticles to be taken up by RPMI8226 cells more efficiently,and these nanoparticles could achieve lysosome escape.The CCK-8 experimental results indicated that BTZ@PLGA-RGD nanoparticles exhibited stronger cytotoxicity against RPMI8226 cells.Conclusion BTZ@PLGA-RGD demonstrates outstanding stability,water solubility,targeting ability,controlled drug-release properties,and biological safety,offering a novel research strategy for MM targeted therapy.